A 15-year prospective study found that a higher level of IgM autoantibodies against LDL, modified by malondialdehyde (MDA-LDL), was associated with a low risk of acute coronary syndrome (relative risk (RR) = 0.79, 95% CI = 0.66–0.95, p = 0.01) and newly diagnosed cardiovascular disease (RR = 0.69, 95% CI = 0.50–0.94, p = 0.02) [30]. The gene discussed is CD40LG; the disease is cardiovascular disorder.